Get started
Author

Jeff Daniel Eskew

Observed names: J. D. Eskew, J.D. Eskew, Jeff D Eskew, Jeff D. Eskew, Jeff Eskew
Observed institutions: Children's Mercy Hospital, The University of Kansas Cancer Center, University of Kansas Medical Center, Poseida Therapeutics (United States), University of Missouri–Kansas City, University of Missouri
ORCID: 0009-0008-2466-1627
Observed ORCID: 0009-0008-2466-1627
OpenAlex ID: A5070318985
Phase I Trial of P-PSMA-101 CAR T Cells in Patients with Metastatic Castration-Resistant Prostate Cancer
2026 · Susan F. Slovin, Xin Gao, et al. · Clinical Cancer Research · 29
Biological characterization of preclinical Bioluminescent Osteosarcoma Orthotopic Mouse (BOOM) model: A multi-modality approach
2013 · Rama Garimella, Jeff Eskew, et al. · Journal of bone oncology · 27
PDF
Clonality studies in giant cell tumor of bone
2002 · H. S. Schwartz, J. D. Eskew, et al. · Journal of Orthopaedic Research® · 26
Hyperbaric oxygen improves engraftment of ex-vivo expanded and gene transduced human CD34+ cells in a murine model of umbilical cord blood transplantation
2013 · Omar S. Aljitawi, Yinghua Xiao, et al. · Blood Cells Molecules and Diseases · 22
PDF
728 Phase 1 study of P-MUC1C-ALLO1 allogeneic CAR-T cells in patients with epithelial-derived cancers
2022 · Jason Henry, David Oh, et al. · Journal for ImmunoTherapy of Cancer · 14
PDF
TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
2025 · Hubert Tseng, Bhagirathbhai Dholaria, et al. · Nature Communications · 10
PDF
A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort
2024 · Bhagirathbhai Dholaria, Leyla O. Shune, et al. · Blood · 10
PDF
46P Development of an allogeneic CAR-T targeting MUC1-C (MUC1, cell surface associated, C-terminal) for epithelial derived tumors
2022 · D. Oh, J. Henry, et al. · Immuno-Oncology Technology · 8
Abstract CT071: Clinical activity of P-BCMA-ALLO1, a B-cell maturation antigen (BCMA) targeted allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed refractory multiple myeloma (RRMM) patients (pts) following progression on prior BCMA targeting therapy
2024 · Bhagirathbhai Dholaria, Leyla Shune, et al. · Cancer Research · 7
OA-04 A Phase 1 Study of P-BCMA- ALLO1, a Non-viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM)
2024 · Bhagirathbhai Dholaria, Mehmet Kocoglu, et al. · Clinical Lymphoma Myeloma & Leukemia · 5
50P Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies
2024 · D. Oh, P. Vu, et al. · Immuno-Oncology Technology · 4
PDF
Tracking hemopexin intracellularly and defining hemopexin protein “interactomes” in human immune and liver cell models
2025 · Bryan Rose, David Moore, et al. · Frontiers in Physiology · 2
P-CD19CD20-ALLO1: Potent Fully Allogeneic CAR-T Therapy Targeting CD19 and CD20 with Superior Efficacy over Single-Target Products
2024 · Samy Jambon, Jennifer Ruiz, et al. · Blood · 2
Abstract CT070: Solid tumor patients require higher cyclophosphamide (cy) dose than multiple myeloma (MM) patients to achieve adequate lymphodepletion (LD) necessary to enable allogeneic CAR-T expansion
2024 · Sabrina Haag, Jeff D. Eskew, et al. · Cancer Research · 2
The Novel Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Engraftment in Irradiated NOD/SCID Mice: What Did We Learn?
2011 · Omar S. Aljitawi, Jeff Radel, et al. · Blood · 1
Supplementary Data from Phase I Trial of P-PSMA-101 CAR T Cells in Patients with Metastatic Castration-Resistant Prostate Cancer
2026 · Susan F. Slovin, Xin Gao, et al.
Data from Phase I Trial of P-PSMA-101 CAR T Cells in Patients with Metastatic Castration-Resistant Prostate Cancer
2026 · Susan F. Slovin, Xin Gao, et al.
Hyperbaric Oxygen Therapy Improves Post-Transplant Umbilical Cord Blood Engraftment
2012 · Omar S. Aljitawi, Xiao Yinghua, et al. · Blood
486 Development of a High-throughput Screening Assay for the Identification of Cancer Cell-specific Hsp90
2012 · Daniel Woodruff, Takrima Sadikot, et al. · The Journal of Urology
Abstract B15: Development of a chimeric saporin peptide which targets human prostatecancer cells via monocyte delivery
2012 · Jeff Eskew, Deryl Troyer, et al. · Cancer Research
Ca2+ transient‐dependent changes in embryonic myocyte proteins during myofibrillogenesis: a proteomic analysis
2007 · Jeff Daniel Eskew, Michael B Ferrari · The FASEB Journal
Ca2+ transient‐dependent changes in embryonic myocyte proteins during myofibrillogenesis a proteomic analysis
2006 · Jeff Daniel Eskew, Michael B Ferrari · The FASEB Journal
Works count: 22
Citation count: 169
H-index: 8
I10-index: 7
Year
Topic
Type